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Abstract: This article reviews recent research on cannabinoid analgesia via the endocannabinoid 
system and non-receptor mechanisms, as well as randomized clinical trials employing canna-
binoids in pain treatment. Tetrahydrocannabinol (THC, Marinol®) and nabilone (Cesamet®) 
are currently approved in the United States and other countries, but not for pain indications. 
Other synthetic cannabinoids, such as ajulemic acid, are in development. Crude herbal cannabis 
remains illegal in most jurisdictions but is also under investigation. Sativex®, a cannabis derived 
oromucosal spray containing equal proportions of THC (partial CB1 receptor agonist ) and can-
nabidiol (CBD, a non-euphoriant, anti-inﬂ  ammatory analgesic with CB1 receptor antagonist 
and endocannabinoid modulating effects) was approved in Canada in 2005 for treatment of 
central neuropathic pain in multiple sclerosis, and in 2007 for intractable cancer pain. Numer-
ous randomized clinical trials have demonstrated safety and efﬁ  cacy for Sativex in central and 
peripheral neuropathic pain, rheumatoid arthritis and cancer pain. An Investigational New 
Drug application to conduct advanced clinical trials for cancer pain was approved by the US 
FDA in January 2006. Cannabinoid analgesics have generally been well tolerated in clinical 
trials with acceptable adverse event proﬁ  les. Their adjunctive addition to the pharmacological 
armamentarium for treatment of pain shows great promise.
Keywords: cannabinoids, tetrahydrocannabinol, cannabidiol, analgesia, pain management, 
multiple sclerosis
Introduction
Chronic pain represents an emerging public health issue of massive proportions, 
particularly in view of aging populations in industrialized nations. Associated facts 
and ﬁ  gures are daunting: In Europe, chronic musculoskeletal pain of a disabling 
nature affects over one in four elderly people (Frondini et al 2007), while ﬁ  gures from 
Australia note that older half of older people suffer persistent pain, and up to 80% in 
nursing home populations (Gibson 2007). Responses to an ABC News poll in the USA 
indicated that 19% of adults (38 million) have chronic pain, and 6% (or 12 million) 
have utilized cannabis in attempts to treat it (ABC News et al 2005).
Particular difﬁ  culties face the clinician managing intractable patients afﬂ  icted with 
cancer-associated pain, neuropathic pain, and central pain states (eg, pain associated 
with multiple sclerosis) that are often inadequately treated with available opiates, 
antidepressants and anticonvulsant drugs. Physicians are seeking new approaches to 
treatment of these conditions but many remain concerned about increasing govern-
mental scrutiny of their prescribing practices (Fishman 2006), prescription drug abuse 
or diversion. The entry of cannabinoid medicines to the pharmacopoeia offers a novel 
approach to the issue of chronic pain management, offering new hope to many, but 
also stoking the ﬂ  ames of controversy among politicians and the public alike.
This article will attempt to present information concerning cannabinoid mechanisms 
of analgesia, review randomized clinical trials (RCTs) of available and emerging Therapeutics and Clinical Risk Management 2008:4(1) 246
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cannabinoid agents, and address the many thorny issues 
that have arisen with clinical usage of herbal cannabis itself 
(“medical marijuana”). An effort will be made to place the 
issues in context and suggest rational approaches that may 
mitigate concerns and indicate how standardized pharma-
ceutical cannabinoids may offer a welcome addition to 
the pharmacotherapeutic armamentarium in chronic pain 
treatment.
Cannabinoids and analgesic 
mechanisms
Cannabinoids are divided into three groups. The ﬁ  rst are natu-
rally occurring 21-carbon terpenophenolic compounds found 
to date solely in plants of the Cannabis genus, currently termed 
phytocannabinoids (Pate 1994). The best known analgesic of 
these is ∆9-tetrahydrocannabinol (henceforth, THC)(Figure 1), 
ﬁ  rst isolated and synthesized in 1964 (Gaoni and Mechoulam 
1964). In plant preparations and whole extracts, its activity 
is complemented by other “minor” phytocannabinoids such 
as cannabidiol (CBD) (Figure 1), cannabis terpenoids and 
ﬂ  avonoids, as will be discussed subsequently.
Long before mechanisms of cannabinoid analgesia were 
understood, structure activity relationships were investi-
gated and a number of synthetic cannabinoids have been devel-
oped and utilized in clinical trials, notably nabilone (Cesamet®, 
Valeant Pharmaceuticals), and ajulemic acid (CT3, IP-751, 
Indevus Pharmaceuticals) (Figure 1).
In 1988, the ﬁ  rst cannabinoid receptor was identiﬁ  ed 
(CB1) (Howlett et al 1988) and in 1993, a second was 
described (CB2) (Munro et al 1993). Both are 7-domain 
G-protein coupled receptors affecting cyclic-AMP, but 
CB1 is more pervasive throughout the body, with particular 
predilection to nociceptive areas of the central nervous 
system and spinal cord (Herkenham et al 1990; Hohmann 
et al 1999), as well as the peripheral nervous system (Fox 
et al 2001; Dogrul et al 2003) wherein synergy of activity 
between peripheral and central cannabinoid receptor func-
tion has been demonstrated (Dogrul et al 2003). CB2, while 
commonly reported as conﬁ  ned to lymphoid and immune 
tissues, is also proving to be an important mediator for 
suppressing both pain and inﬂ  ammatory processes (Mackie 
2006). Following the description of cannabinoid receptors, 
endogenous ligands for these were discovered: anandamide 
(arachidonylethanolamide, AEA) in 1992 in porcine brain 
(Devane et al 1992), and 2-arachidonylglycerol (2-AG) in 
1995 in canine gut tissue (Mechoulam et al 1995) (Figure 1). 
These endocannabinoids both act as retrograde messengers 
on G-protein coupled receptors, are synthesized on demand, 
and are especially active on glutamatergic and GABA-ergic 
synapses. Together, the cannabinoid receptors, their endog-
enous ligands (“endocannabinoids”) and metabolizing 
enzymes comprise the endocannabinoid system (ECS) (Di 
Marzo et al 1998), whose functions have been prosaically 
termed to be “relax, eat, sleep, forget and protect” (p. 528). 
The endocannabinoid system parallels and interacts at many 
points with the other major endogenous pain control systems: 
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Figure 1 Molecular structures of four cannabinoids employed in pain treatment.Therapeutics and Clinical Risk Management 2008:4(1) 247
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endorphin/enkephalin, vanilloid/transient receptor potential 
(TRPV), and inﬂ  ammatory. Interestingly, our ﬁ  rst knowledge 
of each pain system has derived from investigation of natural 
origin analgesic plants, respectively: cannabis (Cannabis 
sativa, C. indica) (THC, CBD and others), opium poppy 
(Papaver somniferun) (morphine, codeine), chile peppers (eg, 
Capsicum annuum, C. frutescens, C. chinense) (capsaicin) 
and willow bark (Salix spp.) (salicylic acid, leading to ace-
tylsalicylic acid, or aspirin). Interestingly, THC along with 
AEA and 2-AG, are all partial agonists at the CB1 receptor. 
Notably, no endocannabinoid has ever been administered 
to humans, possibly due to issues of patentability and lack 
of commercial feasibility (Raphael Mechoulam, pers comm 
2007). For an excellent comprehensive review of the endo-
cannabinoid system, see Pacher et al (2006), while Walker 
and Huang have provided a key review of antinociceptive 
effects of cannabinoids in models of acute and persistent pain 
(Walker and Huang 2002).
A clinical endocannabinoid deﬁ  ciency has been postu-
lated to be operative in certain treatment-resistant conditions 
(Russo 2004), and has received recent support in ﬁ  ndings that 
anandamide levels are reduced over controls in migraineurs 
(Sarchielli et al 2006), that a subset of ﬁ  bromyalgia patients 
reported signiﬁ  cant decreased pain after THC treatment 
(Schley et al 2006), and the active role of the ECS in intestinal 
pain and motility in irritable bowel syndrome (Massa and 
Monory 2006) wherein anecdotal efﬁ  cacy of cannabinoid 
treatments have also been claimed.
The endocannabinoid system is tonically active in con-
trol of pain, as demonstrated by the ability of SR141716A 
(rimonabant), a CB1 antagonist, to produce hyperalgesia upon 
administration to mice (Richardson et al 1997). As mentioned 
above, the ECS is active throughout the neuraxis, including 
integrative functions in the periacqueductal gray (Walker 
et al 1999a; Walker et al 1999b), and in the ventroposterolat-
eral nucleus of the thalamus, in which cannabinoids proved to 
be 10-fold more potent than morphine in wide dynamic range 
neurons mediating pain (Martin et al 1996). The ECS also 
mediates central stress-induced analgesia (Hohmann et al 
2005), and is active in nociceptive spinal areas (Hohmann 
et al 1995; Richardson et al 1998a) including mechanisms 
of wind-up (Strangman and Walker 1999) and N-methyl-D-
aspartate (NMDA) receptors (Richardson et al 1998b). It was 
recently demonstrated that cannabinoid agonists suppress the 
maintenance of vincristine-induced allodynia through activa-
tion of CB1 and CB2 receptors in the spinal cord (Rahn et al 
2007). The ECS is also active peripherally (Richardson et al 
1998c) where CB1 stimulation reduces pain, inﬂ  ammation 
and hyperalgesia. These mechanisms were also proven to 
include mediation of contact dermatitis via CB1 and CB2 with 
beneﬁ  ts of THC noted systemically and locally on inﬂ  am-
mation and itch (Karsak et al 2007). Recent experiments 
in mice have even suggested the paramount importance of 
peripheral over central CB1 receptors in nociception of pain 
(Agarwal et al 2007)
Cannabinoid agonists produce many effects beyond those 
mediated directly on receptors, including anti-inﬂ  ammatory 
effects and interactions with various other neurotransmit-
ter systems (previously reviewed (Russo 2006a)). Brieﬂ  y 
stated, THC effects in serotonergic systems are widespread, 
including its ability to decrease 5-hydroxytryptamine (5-HT) 
release from platelets (Volfe et al 1985), increase its cerebral 
production and decrease synaptosomal uptake (Spadone 
1991). THC may affect many mechanisms of the trigemino-
vascular system in migraine (Akerman et al 2003; Akerman 
et al 2004; Akerman et al 2007; Russo 1998; Russo 2001). 
Dopaminergic blocking actions of THC (Müller-Vahl et al 
1999) may also contribute to analgesic beneﬁ  ts.
The glutamatergic system is integral to development 
and maintenance of neuropathic pain, and is responsible for 
generating secondary and tertiary hyperalgesia in migraine 
and ﬁ  bromyalgia via NMDA mechanisms (Nicolodi et al 
1998). Thus, it is important to note that cannabinoids pre-
synaptically inhibit glutamate release (Shen et al 1996), 
THC produces 30%–40% reduction in NMDA responses, 
and THC is a neuroprotective antioxidant (Hampson et al 
1998). Additionally, cannabinoids reduce hyperalgesia via 
inhibition of calcitonin gene-related peptide (Richardson et al 
1998a). As for Substance P mechanisms, cannabinoids block 
capsaicin-induced hyperalgesia (Li et al 1999), and THC will 
do so at sub-psychoactive doses in experimental animals (Ko 
and Woods 1999). Among the noteworthy interactions with 
opiates and the endorphin/enkephalin system, THC has been 
shown to stimulate beta-endorphin production (Manzanares 
et al 1998), may allow opiate sparing in clinical application 
(Cichewicz et al 1999), prevents development of tolerance to 
and withdrawal from opiates (Cichewicz and Welch 2003), 
and rekindles opiate analgesia after a prior dosage has worn 
off (Cichewicz and McCarthy 2003). These are all promis-
ing attributes for an adjunctive agent in treatment of clinical 
chronic pain states.
The anti-inﬂ  ammatory contributions of THC are also 
extensive, including inhibition of PGE-2 synthesis (Burstein 
et al 1973), decreased platelet aggregation (Schaefer et al 
1979), and stimulation of lipooxygenase (Fimiani et al 
1999). THC has twenty times the anti-inﬂ  ammatory potency Therapeutics and Clinical Risk Management 2008:4(1) 248
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of aspirin and twice that of hydrocortisone (Evans 1991), 
but in contrast to all nonsteroidal anti-inﬂ  ammatory drugs 
(NSAIDs), demonstrates no cyclo-oxygenase (COX) inhibi-
tion at physiological concentrations (Stott et al 2005a).
Cannabidiol, a non-euphoriant phytocannabinoid com-
mon in certain strains, shares neuroprotective effects with 
THC, inhibits glutamate neurotoxicity, and displays anti-
oxidant activity greater than ascorbic acid (vitamin C) or 
tocopherol (vitamin E) (Hampson et al 1998). While THC 
has no activity at vanilloid receptors, CBD, like AEA, is 
a TRPV1 agonist that inhibits fatty acid amidohydrolase 
(FAAH), AEA’s hydrolytic enzyme, and also weakly inhibits 
AEA reuptake (Bisogno et al 2001). These activities reinforce 
the conception of CBD as an endocannabinoid modulator, 
the ﬁ  rst clinically available (Russo and Guy 2006). CBD 
additionally affects THC function by inhibiting ﬁ  rst pass 
hepatic metabolism to the possibly more psychoactive 11-
hydroxy-THC, prolonging its half-life, and reducing associ-
ated intoxication, panic, anxiety and tachycardia (Russo and 
Guy 2006). Additionally, CBD is able to inhibit tumor necro-
sis factor-alpha (TNF-α) in its own right in a rodent model 
of rheumatoid arthritis (Malfait et al 2000). At a time when 
great concern is accruing in relation to NSAIDs in relation 
to COX-1 inhibition (gastrointestinal ulcers and bleeding) 
and COX-2 inhibition (myocardial infarction and cerebrovas-
cular accidents), CBD, like THC, inhibits neither enzyme at 
pharmacologically relevant doses (Stott et al 2005a). A new 
explanation of inﬂ  ammatory and analgesic effects of CBD 
has recently come to light with the discovery that it is able to 
promote signaling of the adenosine receptor A2A by inhibit-
ing the adenosine transporter (Carrier et al 2006).
Other “minor phytocannabinoids” in cannabis may also 
contribute relevant activity (McPartland and Russo 2001). 
Cannabichromene (CBC) is the third most prevalent canna-
binoid in cannabis, and is also anti-inﬂ  ammatory (Wirth et al 
1980), and analgesic, if weaker than THC (Davis and Hatoum 
1983). Cannabigerol (CBG) displays sub-micromolar afﬁ  n-
ity for CB1 and CB2 (Gauson et al 2007). It also exhibits 
GABA uptake inhibition to a greater extent than THC or 
CBD (Banerjee et al 1975), suggesting possible utilization as 
a muscle relaxant in spasticity. Furthermore, CBG has more 
potent analgesic, anti-erythema and lipooxygenase blocking 
activity than THC (Evans 1991), mechanisms that merit 
further investigation. It requires emphasis that drug stains of 
North American (ElSohly et al 2000; Mehmedic et al 2005), 
and European (King et al 2005) cannabis display relatively 
high concentrations of THC, but are virtually lacking in CBD 
or other phytocannabinoid content.
Cannabis terpenoids also display numerous attributes that 
may be germane to pain treatment (McPartland and Russo 
2001). Myrcene is analgesic, and such activity, in contrast 
to cannabinoids, is blocked by naloxone (Rao et al 1990), 
suggesting an opioid-like mechanism. It also blocks inﬂ  am-
mation via PGE-2 (Lorenzetti et al 1991). The cannabis 
sesquiterpenoid β-caryophyllene shows increasing promise in 
this regard. It is anti-inﬂ  ammatory comparable to phenylbu-
tazone via PGE-1 (Basile et al 1988), but simultaneously acts 
as a gastric cytoprotective (Tambe et al 1996). The analgesic 
attributes of β-caryophyllene are increasingly credible with 
the discovery that it is a selective CB2 agonist (Gertsch et al 
2007), with possibly broad clinical applications. α-Pinene 
also inhibits PGE-1 (Gil et al 1989), while linalool displays 
local anesthetic effects (Re et al 2000).
Cannabis ﬂ  avonoids in whole cannabis extracts may also 
contribute useful activity (McPartland and Russo 2001). 
Apigenin inhibits TNF-α (Gerritsen et al 1995), a mecha-
nism germane to multiple sclerosis and rheumatoid arthritis. 
Cannﬂ  avin A, a ﬂ  avone unique to cannabis, inhibits PGE-2 
thirty times more potently than aspirin (Barrett et al 1986), 
but has not been subsequently investigated.
Finally, β-sitosterol, a phytosterol found in cannabis, 
reduced topical inﬂ  ammation 65% and chronic edema 41% 
in skin models (Gomez et al 1999).
Available cannabinoid analgesic 
agents and those in development
Very few randomized controlled trials (RCTs) have been con-
ducted using smoked cannabis (Campbell et al 2001) despite 
many anecdotal claims (Grinspoon and Bakalar 1997). One 
such study documented slight weight gain in HIV/AIDS 
subjects with no signiﬁ  cant immunological sequelae (Abrams 
et al 2003). A recent brief trial of smoked cannabis (3.56% 
THC cigarettes 3 times daily) in HIV-associated neuropathy 
showed positive results on daily pain, hyperalgesia and 30% 
pain reduction (vs 15% in placebo) in 50 subjects over a treat-
ment course of only 5 days (Abrams et al 2007) (Table 1). 
This short clinical trial also demonstrated prominent adverse 
events associated with intoxication. In Canada, 21 subjects 
with chronic pain sequentially smoked single inhalations of 
25 mg of cannabis (0, 2.5, 6.0, 9.5% THC) via a pipe three 
times a day for 5 days to assess effects on pain (Ware et al 
2007) with results the authors termed “modest”: no changes 
were observed in acute neuropathic pain scores, and a very 
low number of subjects noted 30% pain relief at the end of the 
study (Table 1). Even after political and legal considerations, 
it remains extremely unlikely that crude cannabis could Therapeutics and Clinical Risk Management 2008:4(1) 249
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Table 1 Results RCTs of cannabinoids in treatment of pain syndromes ()
Drug  Subject number  RCT indication  Trial duration  Results/Reference
 N  =
Ajulemic  21  Neuropathic pain  7 day crossover  VAS improved over placebo
Acid       (p  = 0.02) (Karst et al 2003)
Cannabis,   50  HIV neuropathy  5 days  Decreased daily pain 
smoked       (p  = 0.03) and hyperalgesia 
       (p  = 0.05), 52% with  30% 
        pain reduction vs placebo 
       (p  = 0.04) (Abrams et al 2007)
Cannabis,  21  Chronic neuropathic   5 days  No acute beneﬁ  t on pain, 
Smoked    pain    average daily pain lower on high
        THC cannabis vs placebo
       (p  = 0.02 ) (Ware et al 2007)
Cannador  419  Pain due to spasm in   15 weeks  Improvement over placebo
    MS    in subjective pain associated
       with  spasm  (p  = 0.003)
        (Zajicek et al 2003)
Cannador  65  Post-herpetic   4 weeks  No beneﬁ  t observed 
    neuralgia    (Ernst et al 2005)
Cannador  30  Post-operative pain  Single doses,   Decreasing pain intensity 
      daily  with increased dose 
       (p  = 0.01)(Holdcroft et al 2006)
Marinol  24  Neuropathic pain in   15–21 days,   Median numerical pain 
   MS  crossover  (p  = 0.02), median pain relief 
       improved  (p  = 0.035) over 
        placebo (Svendsen et al 2004)
Marinol  40  Post-operative pain  Single dose  No beneﬁ  t observed over 
        placebo (Buggy et al 2003)
Nabilone  41  Post-operative pain  3 doses in 24   NSD morphine 
     hours  consumption.  Increased 
        pain at rest and on 
        movement with nabilone 1
        or 2 mg (Beaulieu 2006)
Sativex  20  Neurogenic pain  Series of 2-week   Improvement with Tetranabinex
      N-of-1 crossover   and Sativex on VAS
      blocks  pain vs placebo (p   0.05),
        symptom control best with Sativex
       (p    0.0001) (Wade et al 2003)
Sativex  24  Chronic intractable   12 weeks, series   VAS pain improved over placebo
    pain  of N-of-1   (p   0.001) especially in MS
     crossover  blocks  (p    0.0042) (Notcutt et al 2004)
Sativex  48  Brachial plexus   6 weeks in 3 two-  Beneﬁ  ts noted in Box 
    avulsion  week crossover   Scale-11 pain scores with 
     blocks  Tetranabinex  (p  = 0.002) and 
       Sativex  (p  = 0.005) over 
        placebo (Berman et al 2004)
Sativex  66  Central neuropathic   5 weeks  NRS analgesia improved 
    pain in MS    over placebo (p = 0.009) 
        (Rog et al 2005)
Sativex  125  Peripheral   5 weeks  Improvements in NRS pain 
   neuropathic  pain    levels  (p  = 0.004), dynamic 
       allodynia  (p  = 0.042), and 
       punctuate  allodynia 
       (p  = 0.021) vs placebo 
        (Nurmikko et al 2007)
Sativex  56  Rheumatoid arthritis  Nocturnal dosing   Improvements over placebo 
      for 5 weeks  morning pain on movement 
       (p  = 0.044), morning pain at 
       rest  (p  = 0.018), DAS-28 
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ever be approved by the FDA as a prescription medicine as 
outlined in the FDA Botanical Guidance document (Food 
and Drug Administration 2004; Russo 2006b), due to a 
lack of rigorous standardization of the drug, an absence of 
Phase III clinical trials, and pulmonary sequelae (bronchial 
irritation and cough) associated with smoking (Tashkin 
2005). Although cannabis vaporizers reduce potentially 
carcinogenic polyaromatic hydrocarbons, they have not been 
totally eliminated by this technology (Gieringer et al 2004; 
Hazekamp et al 2006).
Oral dronabinol (THC) is marketed in synthetic form 
as Marinol® (Solvay Pharmaceuticals) in various countries, 
and was approved in the USA for nausea associated with 
chemotherapy in 1985, and in 1992 for appetite stimula-
tion in HIV/AIDS. Oral dronabinol’s expense, variability 
of action, and attendant intoxication and dysphoria have 
limited its adoption by clinicians (Calhoun et al 1998). Two 
open label studies in France of oral dronabinol for chronic 
neuropathic pain in 7 subjects (Clermont-Gnamien et al 
2002) and 8 subjects (Attal et al 2004), respectively, failed 
to show signiﬁ  cant beneﬁ  t on pain or other parameters, and 
showed adverse event frequently requiring discontinuation 
with doses averaging 15–16.6 mg THC. Dronabinol did dem-
onstrate positive results in a clinical trial of multiple sclerosis 
pain in two measures (Svendsen et al 2004), but negative 
results in post-operative pain (Buggy et al 2003) (Table 1). 
Another uncontrolled case report in three subjects noted relief 
of intractable pruritus associated with cholestatic jaundice 
employing oral dronabinol (Neff et al 2002). Some authors 
have noted patient preference for whole cannabis prepara-
tions over oral THC (Joy et al 1999), and the contribution 
of other components beyond THC to therapeutic beneﬁ  ts 
(McPartland and Russo 2001). Inhaled THC leads to peak 
plasma concentration within 3–10 minutes, followed by a 
rapid fall while levels of intoxication are still rising, and with 
systemic bioavailability of 10%–35% (Grotenhermen 2004). 
THC absorption orally is slow and erratic with peak serum 
levels in 45–120 minutes or longer. Systemic bioavailability 
is also quite low due to rapid hepatic metabolism on ﬁ  rst pass 
to 11-hydroxy-THC. A rectal suppository of THC-hemis-
uccinate is under investigation (Broom et al 2001), as are 
transdermal delivery techniques (Challapalli and Stinchcomb 
2002). The terminal half-life of THC is quite prolonged due 
to storage in body lipids (Grotenhermen 2004).
Nabilone (Cesamet) (Figure 1), is a synthetic dimethyl-
heptyl analogue of THC (British Medical Association 1997) 
that displays greater potency and prolonged half-life. Serum 
levels peak in 1–4 hours (Lemberger et al 1982). It was also 
primarily developed as an anti-emetic in chemotherapy, and 
was recently re-approved for this indication in the USA. Prior 
case reports have noted analgesic effects in case reports in 
neuropathic pain (Notcutt et al 1997) and other pain disorders 
(Berlach et al 2006). Sedation and dysphoria were prominent 
sequelae. An RCT of nabilone in 41 post-operative subjects 
actually documented exacerbation of pain scores after thrice 
daily dosing (Beaulieu 2006) (Table 1). An abstract of a study 
Table 1 (Continued)
Drug  Subject number  RCT indication  Trial duration  Results/Reference
       (p  = 0.002), and SF-MPQ 
        pain at present (p = 0.016) 
        (Blake et al 2006)
Sativex  117  Pain after spinal   10 days  NSD in NRS pain socres, 
    injury    but improved Brief Pain 
       Inventory  (p  = 0.032), and 
        Patients Global Impression 
        of Change (p = 0.001) 
       (unpublished)
Sativex  177  Intractable cancer   2 weeks  Improvements in NRS 
    pain    analgesia vs placebo 
       (p  = 0.0142), Tetranabinex 
        NSD (Johnson and Potts 2005)
Sativex  135  Intractable lower   8 weeks  Improved bladder severity 
    urinary tract     symptoms including pain 
    symptoms in MS    over placebo (p = 0.001) 
       (unpublished)
Abbreviations: MS, multiple sclerosis; NRS, numerical rating scale; NSD, no signiﬁ  cant difference; RCTs, randomized clinical trials;   VAS, visual analogue pain scales.Therapeutics and Clinical Risk Management 2008:4(1) 251
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of 82 cancer patients on nabilone claimed improvement in 
pain levels after varying periods of follow-up compared to 
patients treated without this agent (Maida 2007). However, 17 
subjects dropped out, and the study was neither randomized 
nor controlled, and therefore is not included in Table 1.
Ajulemic acid (CT3, IP-751) (Figure 1), another syn-
thetic dimethylheptyl analogue, was employed in a Phase 
II RCT in 21 subjects with improvement in peripheral 
neuropathic pain (Karst et al 2003) (Table 1). Part of its 
analgesic activity may relate to binding to intracellular 
peroxisome proliferator-activator receptor gamma (Liu 
et al 2003). Peak plasma concentrations have generally 
been attained in 1–2 hours, but with delays up to 4–5 hours 
is some subjects (Karst et al 2003). Debate surrounds the 
degree of psychoactivity associated with the drug (Dyson 
et al 2005). Current research is conﬁ  ned to the indication 
of interstitial cystitis.
Cannador® (IKF-Berlin) is a cannabis extract administered 
in oral capsules, with differing ﬁ  gures as to THC:CBD ratios 
(reviewed in (Russo and Guy 2006)), generally approximately 
2:1. Two pharmacokinetic studies on possibly related mate-
rial have been reported (Nadulski et al 2005a; Nadulski 
et al 2005b). In a Phase III RCT employing Cannador in 
spasticity in multiple sclerosis (MS) (CAMS) (Zajicek et al 
2003) (Table 1), no improvement was noted in the Ashworth 
Scale, but beneﬁ  t was observed in spasm-associated pain on 
subjective measures. Both Marinol and Cannador produced 
reductions in pain scores in long-term follow-up (Zajicek et al 
2005). Cannador was assayed in postherpetic neuralgia in 65 
subjects with no observed beneﬁ  t (Ernst et al 2005) (Table 
1), and in 30 post-operative pain subjects (CANPOP) with-
out opiates, with slight beneﬁ  ts, but prominent psychoactive 
sequelae (Holdcroft et al 2006) (Table 1).
Sativex® (GW Pharmaceuticals) is an oromucosal whole 
cannabis-based spray combining a CB1 partial agonist (THC) 
with a cannabinoid system modulator (CBD), minor can-
nabinoids and terpenoids plus ethanol and propylene glycol 
excipients and peppermint ﬂ  avoring (McPartland and Russo 
2001; Russo and Guy 2006). It was approved by Health 
Canada in June 2005 for prescription for central neuropathic 
pain in multiple sclerosis, and in August 2007, it was addi-
tionally approved for treatment of cancer pain unresponsive 
to optimized opioid therapy. Sativex is a highly standardized 
pharmaceutical product derived from two Cannabis sativa 
chemovars following Good Agricultural Practice (GAP) (de 
Meijer 2004), yielding Tetranabinex® (predominantly-THC 
extract) and Nabidiolex® (predominantly-CBD extract) in 
a 1:1 ratio. Each 100 µL pump-action oromucosal Sativex 
spray actuation provides 2.7 mg of THC and 2.5 mg of CBD. 
Pharmacokinetic data are available, and indicate plasma half 
lives of 85 minutes for THC, 130 minutes for 11-hydroxy-
THC and 100 minutes for CBD (Guy and Robson 2003). 
Sativex effects commence in 15–40 minutes, an interval that 
permits symptomatic dose titration. A very favorable adverse 
event proﬁ  le has been observed in over 2500 patient years 
of exposure in over 2000 experimental subjects. Patients 
most often ascertain an individual stable dosage within 
7–10 days that provides therapeutic relief without unwanted 
psychotropic effects (often in the range of 8–10 sprays per 
day). In all RCTs, Sativex was adjunctively added to opti-
mal drug regimens in subjects with intractable symptoms, 
those often termed “untreatable.” Sativex is also available 
by named patient prescription in the UK and the Catalonia 
region of Spain. An Investigational New Drug (IND) applica-
tion to study Sativex in advanced clinical trials in the USA 
was approved by the FDA in January 2006 in patients with 
intractable cancer pain.
The clinical trials performed with Sativex have recently 
been assessed in two independent review articles (Barnes 
2006; Pérez 2006). In a Phase II clinical trial in 20 patients 
with neurogenic symptoms (Wade et al 2003), Tetranabinex, 
Nabidiolex, and Sativex were tested in a double-blind RCT 
vs placebo (Table 1). Signiﬁ  cant improvement was seen with 
both Tetranabinex and Sativex on pain (especially neuro-
pathic), but post-hoc analysis showed symptom control was 
best with Sativex (p   0.0001), with less intoxication than 
with THC-predominant extract.
In a Phase II double-blind crossover study of intractable 
chronic pain (Notcutt et al 2004) in 24 subjects, visual 
analogue scales (VAS) were 5.9 for placebo, 5.45 for 
Nabidiolex, 4.63 for Tetranabinex and 4.4 for Sativex extracts 
(p   0.001). Sativex produced best results for pain in MS 
subjects (p   0.0042) (Table 1).
In a Phase III study of pain associated due to brachial 
plexus avulsion (N = 48) (Berman et al 2004), fairly com-
parable beneﬁ  ts were noted in Box Scale-11 pain scores with 
Tetranabinex and Sativex extracts (Table 1).
In a controlled double-blind RCT of central neuropathic 
pain, 66 MS subjects showed mean Numerical Rating Scale 
(NRS) analgesia favoring Sativex over placebo (Rog et al 
2005) (Table 1).
In a Phase III double-blind, placebo-controlled trial 
(N = 125) of peripheral neuropathic pain with allodynia 
(Nurmikko et al 2007), Sativex produced highly statisti-
cally signiﬁ  cant improvements in pain levels, dynamic and 
punctate allodynia (Table 1).Therapeutics and Clinical Risk Management 2008:4(1) 252
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In a SAFEX study of Phase III double-blind RCT in 160 
subjects with various symptoms of MS (Wade et al 2004), 
137 patients elected to continue on Sativex after the initial 
study (Wade et al 2006). Rapid declines were noted in the ﬁ  rst 
twelve weeks in pain VAS (N = 47) with slower sustained 
improvements for more than one year. During that time, 
there was no escalation of dose indicating an absence of 
tolerance to the preparation. Similarly, no withdrawal effects 
were noted in a subset of patients who voluntarily stopped 
the medicine abruptly. Upon resumption, beneﬁ  ts resumed 
at the prior established dosages.
In a Phase II double-blind, randomized, placebo-
controlled, 5-week study of 56 rheumatoid arthritis patients 
with Sativex (Blake et al 2006), employed nocturnal treat-
ment only to a maximum of 6 sprays per evening (16.2 mg 
THC + 15 mg CBD). In the ﬁ  nal treatment week, morning 
pain on movement, morning pain at rest, DAS-28 measure 
of disease activity, and SF-MPQ pain at present all favored 
Sativex over placebo (Table 1).
Results of a Phase III study (N = 177) comparing Sativex, 
THC-predominant extract and placebo in intractable pain due 
to cancer unresponsive to opiates (Johnson and Potts 2005) 
demonstrated that Sativex produced highly statistically sig-
niﬁ  cant improvements in analgesia (Table 1), while the THC-
predominant extract failed to produce statistical demarcation 
from placebo, suggesting the presence of CBD in the Sativex 
preparation was crucial to attain signiﬁ  cant pain relief.
In a study of spinal injury pain, NRS of pain were not 
statistically different from placebo, probably due to the short 
duration of the trial, but secondary endpoints were clearly 
positive (Table 1). Finally, in an RCT of intractable lower 
urinary tract symptoms in MS, accompanying pain in affected 
patients was prominently alleviated (Table 1).
Highly statistically signiﬁ  cant improvements have been 
observed in sleep parameters in virtually all RCTs performed 
with Sativex in chronic pain conditions leading to reduced 
“symptomatic insomnia” due to symptom reduction rather 
than sedative effects (Russo et al 2007).
Common adverse events (AE) of Sativex acutely in 
RCTs have included complaints of bad taste, oral stinging, 
dry mouth, dizziness, nausea or fatigue, but do not generally 
necessitate discontinuation, and prove less common over time. 
While there have been no head-to-head comparative RCTs of 
Sativex with other cannabinoid agents, certain contrasts can 
be drawn. Sativex (Rog et al 2005) and Marinol (Svendsen 
et al 2004) have both been examined in treatment of central 
neuropathic pain in MS, with comparable results (Table 1). 
However, adverse events were comparable or greater with 
Marinol than with Sativex employing THC dosages some 
2.5 times higher due to the presence of accompanying CBD 
(Russo 2006b; Russo and Guy 2006).
Similarly, while Sativex and smoked cannabis have not 
been employed in the same clinical trial, comparisons of side 
effect proﬁ  les can be made on the basis of SAFEX studies 
of Sativex for over a year and up to several years in MS 
and other types of neuropathic pain (Russo 2006b; Wade 
et al 2006), and government-approved research programs 
employing standardized herbal cannabis from Canada for 
chronic pain (Lynch et al 2006) and the Netherlands for 
general conditions (Janse et al 2004; Gorter et al 2005) over 
a period of several months or more. As is evident in Figure 2 
(Figure 2), all adverse events are more frequently reported 
with herbal cannabis, except for nausea and dizziness, both 
early and usually transiently reported with Sativex (see 
(Russo 2006b) for additional discussion).
Practical issues with cannabinoid 
medicines
Phytocannabinoids are lipid soluble with slow and erratic 
oral absorption. While cannabis users claim that the smok-
ing of cannabis allows easy dose titration as a function of 
rapid onset, high serum levels in a short interval inevitably 
result. This quick onset is desirable for recreational purposes, 
wherein intoxication is the ultimate goal, but aside from 
paroxysmal disorders (eg, episodic trigeminal neuralgia or 
cluster headache attack), such rapid onset of activity is not 
usually necessary for therapeutic purposes in chronic pain 
states. As more thoroughly reviewed elsewhere (Russo 
2006b), cannabis smoking produces peak levels of serum 
THC above 140 ng/mL (Grotenhermen 2003; Huestis 
et al 1992), while comparable amounts of THC in Sativex 
administered oromucosally remained below 2 ng/mL (Guy 
and Robson 2003).
The vast majority of subjects in Sativex clinical trials do 
not experience psychotropic effects outside of initial dose 
titration intervals (Figure 2) and most often report subjec-
tive intoxication levels on visual analogue scales that are 
indistinguishable from placebo, in the single digits out of 
100 (Wade et al 2006). Thus, it is now longer tenable to 
claim that psychoactive effects are a necessary prerequisite to 
symptom relief in the therapeutic setting with a standardized 
intermediate onset cannabis-based preparation. Intoxication 
has remained a persistent issue in Marinol usage (Calhoun 
et al 1998), in contrast.
Recent controversies have arisen in relation to non-
steroidal anti-inﬂ  ammatory drugs (NSAID), with concerns Therapeutics and Clinical Risk Management 2008:4(1) 253
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that COX-1 agents may provoke gastrointestinal ulceration 
and bleeding, and COX-2 drugs may increase incidents 
of myocardial infarction and cerebrovascular accidents 
(Fitzgerald 2004; Topol 2004). In contrast, neither THC nor 
CBD produce signiﬁ  cant COX inhibition at normal dosage 
levels (Stott et al 2005a).
Frequent questions have been raised as to whether 
psychoactive drugs may be adequately blinded (masked) in 
randomized clinical trials. Internal review and outside analy-
sis have conﬁ  rmed that blinding in Sativex spasticity studies 
has been effective (Clark and Altman 2006; Wright 2005). 
Sativex and its placebo are prepared to appear identical in 
taste and color. About half of clinical trial subjects reported 
previous cannabis exposure, but results of two studies 
(Rog et al 2005; Nurmikko et al 2007) support the fact that 
cannabis-experienced and naïve patients were identical in 
observed efﬁ  cacy and adverse event reporting
Great public concern attends recreational cannabis 
usage and risks of dependency. The addictive potential of a 
drug is assessed on the basis of ﬁ  ve elements: intoxication, 
reinforcement, tolerance, withdrawal and dependency. Drug 
abuse liability (DAL) is also assessed by examining a drug’s 
rates of abuse and diversion. US Congress placed cannabis 
in Schedule I of the Controlled Substances Act in 1970, with 
drugs categorized as addictive, dangerous, possessing severe 
abuse potential and no recognized medical value. Marinol 
was placed in Schedule II, the category for drugs with high 
abuse potential and liability to produce dependency, but 
certain recognized medical uses, after its FDA approval in 
1985. Marinol was reassigned to Schedule III in 1999, a 
category denoting a lesser potential for abuse or lower depen-
dency risk after documentation that little abuse or diversion 
(Calhoun et al 1998) had occurred. Nabilone was placed and 
has remained in Schedule II since 1985.
The degree to which a drug is reinforcing is determined 
partly by the by the rate of its delivery to the brain (Samaha and 
Robinson 2005). Sativex has effect onset in 15–40 minutes, 
peaking in a few hours, quite a bit slower than drugs of high 
abuse potential. It has been claimed that inclusion of CBD 
diminishes psychoactive effects of THC, and may lower 
potential drug abuse liability of the preparation (see Russo 
(2006b)) for discussion). Prior studies from Sativex clinical 
trials do not support the presence reinforcement or euphoria 
as problems in administration (Wade et al 2006).
Certain facets of acute cannabinoid exposure, including 
tachycardia, hypothermia, orthostatic hypotension, dry mouth, 
ocular injection, intraocular pressure decreases, etc. are subject 
to rapid tachyphylaxis upon continued administration (Jones 
et al 1976). No dose tolerance to the therapeutic effects of 
Sativex has been observed in clinical trials in over 1500 patient-
years of administration. Additionally, therapeutic efﬁ  cacy has 
been sustained for several years in a wide variety of symp-
toms; SAFEX studies in MS and peripheral neuropathic pain, 
conﬁ  rm that Sativex doses remain stable or even decreased 
after prolonged usage (Wade et al 2006), with maintenance of 
therapeutic beneﬁ  t and even continued improvement.
Debate continues as to the existence of a clinically 
signiﬁ  cant cannabis withdrawal syndrome with proponents 
(Budney et al 2004), and questioners (Smith 2002). While 
withdrawal effects have been reported in recreational can-
nabis smokers (Solowij et al 2002), 24 volunteers with MS 
who abruptly stopped Sativex after more than a year of 
continuous usage displayed no withdrawal symptoms meet-
ing Budney’s criteria. While symptoms recurred after 7–10 
days of abstinence from Sativex, prior levels of symptom 
control were readily re-established upon re-titration of the 
agent (Wade et al 2006).
Overall, Sativex appears to pose less risk of dependency 
than smoked cannabis based on its slower onset, lower dos-
age utilized in therapy, almost total absence of intoxication 
in regular usage, and minimal withdrawal symptomatol-
ogy even after chronic administration. No known abuse or 
diversion incidents have been reported with Sativex to date 
(as of November 2007). Sativex is expected to be placed 
in Schedule IV of the Misuse of Drugs Act in the United 
Kingdom once approved.
Cognitive effects of cannabis have been reviewed (Russo 
et al 2002; Fride and Russo 2006), but less study has occurred 
in therapeutic contexts. Effects of chronic heavy recreational 
cannabis usage on memory abate without sequelae after a few 
weeks of abstinence (Pope et al 2001). Studies of components 
of the Halstead-Reitan battery with Sativex in neuropathic 
pain with allodynia have revealed no changes vs placebo 
(Nurmikko et al 2007), and in central neuropathic pain in 
MS (Rog et al 2005), 4 of 5 tests showed no signiﬁ  cant 
differences. While the Selective Reminding Test did not 
change signiﬁ  cantly on Sativex, placebo patients displayed 
unexpected improvement.
Slight improvements were observed in Hospital Anxiety 
and Depression Scales depression and anxiety scores were 
noted with Sativex in MS patients with central neuropathic 
pain (Rog et al 2005), although not quite statistically 
signiﬁ  cant. No long-term mood disorders have been associ-
ated with Sativex administration.
Debate continues with regard to the relationship between 
cannabis usage and schizophrenia (reviewed (Fride and Therapeutics and Clinical Risk Management 2008:4(1) 255
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Russo 2006)). An etiological relationship is not supported 
by epidemiological data (Degenhardt et al 2003), but if 
present, should bear relation to dose and length of high 
exposure. It is likely that lower serum levels of Sativex 
in therapeutic usage, in conjunction with anti-psychotic 
properties of CBD (Zuardi and Guimaraes 1997), would 
minimize risks. Children and adolescents have been 
excluded from Sativex RCTs to date. SAFEX studies of 
Sativex have yielded few incidents of thought disorder, 
paranoia or related complaints.
Adverse effects of cannabinoids on immune function 
have been observed in experimental animals at doses 
50–100 times the psychoactive level (Cabral 2001). In four 
patients using herbal cannabis therapeutically for over 20 
years, no abnormalities were observed in leukocyte, CD4 
or CD8 cell counts (Russo et al 2002). Investigation of MS 
patients on Cannador revealed no major immune changes 
(Katona et al 2005), and similarly, none occurred with 
smoked cannabis in a short-term study of HIV patients 
(Abrams et al 2003). Hematological measures have been 
normal in all Sativex RCTs without clinical signs of immune 
dysfunction.
Concerns are frequently noted with new drug-drug inter-
actions, but few have resulted in Sativex RCTs despite its 
adjunctive use with opiates, many other psychoactive analge-
sic, antidepressant and anticonvulsant drugs (Russo 2006a), 
possibly due to CBD ability to counteract sedative effects 
of THC (Nicholson et al 2004). No effects of THC extract, 
CBD extract or Sativex were observed in a study of effects 
on the hepatic cytochrome P450 complex (Stott et al 2005b). 
On additional study, at 314 ng/ml cannabinoid concentration, 
Sativex and components produced no signiﬁ  cant induction 
on human CYP450 (Stott et al 2007). Thus, Sativex should 
be safe to use in conjunction with other drugs metabolized 
via this pathway.
The Marinol patient monograph cautions that patients 
should not drive, operate machinery or engage in hazardous 
activities until accustomed to the drug’s effects (http://www.
solvaypharmaceuticals-us.com/static/wma/pdf/1/3/1/9/
Marinol5000124ERev52003.pdf ). The Sativex product 
monograph in Canada (http://www.bayerhealth.ca/display.
cfm?Object_ID=272&Article_ID=121&expandMenu_
ID=53&prevSubItem=5_52 ) suggests that patients taking 
it should not drive automobiles. Given that THC is the most 
active component affecting such abilities, and the low serum 
levels produced in Sativex therapy (vide supra), it would be 
logical that that patients may be able to safely engage in such 
activities after early dose titration and according to individual 
circumstances, much as suggested for oral dronabinol. This 
is particularly the case in view of a report by an expert panel 
(Grotenhermen et al 2005) that comprehensively analyzed 
cannabinoids and driving. It suggested scientiﬁ  c standards 
such as roadside sobriety tests, and THC serum levels of 7–10 
ng/mL or less, as reasonable approaches to determine rela-
tive impairment. No studies have demonstrated signiﬁ  cant 
problems in relation to cannabis affecting driving skills at 
plasma levels below 5 ng/mL of THC. Prior studies document 
that 4 rapid oromucosal sprays of Sativex (greater than the 
average single dose employed in therapy) produced serum 
levels well below this threshold (Russo 2006b). Sativex is 
now well established as a cannabinoid agent with minimal 
psychotropic effect.
Cannabinoids may offer significant “side benefits” 
beyond analgesia. These include anti-emetic effects, well 
established with THC, but additionally demonstrated for 
CBD (Pertwee 2005), the ability of THC and CBD to pro-
duce apoptosis in malignant cells and inhibit cancer-induced 
angiogenesis (Kogan 2005; Ligresti et al 2006), as well as the 
neuroprotective antioxidant properties of the two substances 
(Hampson et al 1998), and improvements in symptomatic 
insomnia (Russo et al 2007).
The degree to which cannabinoid analgesics will be 
adopted into adjunctive pain management practices currently 
remains to be determined. Data on Sativex use in Canada 
for the last reported 6-month period (January-July 2007) 
indicated that 81% of prescriptions issued for patients in 
that interval were reﬁ  lls (data on ﬁ  le, from Brogan Inc Rx 
Dynamics), thus indicating in some degree an acceptance 
of, and a desire to, continue such treatment. Given their 
multi-modality effects upon various nociceptive pathways, 
their adjunctive side beneﬁ  ts, the efﬁ  cacy and safety proﬁ  les 
to date of speciﬁ  c preparations in advanced clinical trials, 
and the complementary mechanisms and advantages of their 
combination with opioid therapy, the future for cannabinoid 
therapeutics appears very bright, indeed.
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